This blog features:
- A comprehensive overview and detailed insights into VigiBase
- Key statistics and global data related to VigiBase
- The critical role and importance of VigiBase in pharmacovigilance and drug safety monitoring
Introduction to VigiBase
Why VigiBase is Important in Pharmacovigilance
Pharmacovigilance depends on the continuous monitoring and sharing of adverse event information to ensure the safe use of medicines and vaccines worldwide. Detecting rare or previously unidentified adverse reactions often requires global collaboration and large-scale safety data collection.
To support this mission, the World Health Organization (WHO) established VigiBase — the world’s largest global database of individual case safety reports (ICSRs).
What is VigiBase?
VigiBase is the WHO global database of Individual Case Safety Reports (ICSRs), maintained by the Uppsala Monitoring Centre (UMC), Sweden, the WHO Collaborating Centre for International Drug Monitoring.
The database was created under the WHO Programme for International Drug Monitoring (WHO PIDM), which was established following the World Health Assembly Resolution WHA 16.36 in 1963. The programme enables WHO Member States and territories to collaborate in pharmacovigilance activities and strengthen global medicine safety monitoring.
Currently, over 152 countries and territories contribute to VigiBase, making it one of the largest international pharmacovigilance networks in the world.
“Every adverse event report shared today may prevent a patient harm tomorrow — that is the power of VigiBase.”
How the WHO Programme for International Drug Monitoring Works
Within the WHO PIDM, participating countries are represented by National Regulatory Authorities (NRAs) and, in some cases, National Immunization Programmes (NIPs) officially designated by their governments.
The World Health Organization (WHO) oversees the governance and policy aspects of the programme, while the Uppsala Monitoring Centre (UMC) manages the operational activities, including:
- Maintaining VigiBase
- Developing pharmacovigilance tools and systems
- Conducting signal detection and safety research
- Providing pharmacovigilance training and support
- Assisting countries in collecting, managing, and analysing safety data
Key Features and Importance of VigiBase
1. WHO Global Database of ICSRs
VigiBase serves as the WHO global repository for Individual Case Safety Reports related to medicines, vaccines, biological products, and traditional medicines.
2. Over 30 Million Adverse Event Reports
The database currently contains more than 30 million reports of suspected adverse drug reactions (ADRs) and adverse events following immunization (AEFIs) submitted from participating countries worldwide.
3. Global Participation and Collaboration
Currently, 152 countries and territories contribute safety reports to VigiBase, creating a strong international pharmacovigilance collaboration network.
4. Supports Signal Detection and Risk Identification
Safety reports submitted to VigiBase are regularly screened and analysed to identify new safety signals, emerging risks, and previously unknown medicine-related problems.
5. Valuable Resource for Medicine Safety Monitoring
VigiBase acts as a critical reference source for regulatory authorities, healthcare professionals, researchers, and pharmaceutical companies to evaluate medicine safety trends globally and nationally.
6. Integration with VigiFlow
Many member countries use VigiFlow, a web-based adverse event management system developed by UMC, to collect and process ICSRs before submission to VigiBase. VigiFlow supports multiple languages, including English, French, Spanish, and Russian.
7. Enhances Public Health Protection
By enabling rapid identification of safety concerns, VigiBase contributes significantly to patient safety, regulatory decision-making, and the safe use of medicinal products worldwide.
Additional Important Facts About VigiBase
- VigiBase uses standardized medical coding systems such as MedDRA.
- It supports both medicine and vaccine safety monitoring.
- Data from VigiBase contributes to WHO safety communications and scientific research.
- The database plays a vital role in global signal management and benefit-risk evaluation.
Conclusion
VigiBase is one of the most important tools in global pharmacovigilance and medicine safety monitoring. Through the collaboration of 152 countries and territories, it enables the collection and analysis of millions of adverse event reports from around the world.
By supporting early signal detection, international data sharing, and evidence-based regulatory decisions, VigiBase plays a major role in protecting public health and improving the safe use of medicines and vaccines globally.
